IMPRS-IS scholars are invited to join us on a bus trip to visit to Boehringer Ingelheim's Biberach site, the company's largest research and development center worldwide.
We are excited to invite you on an exclusive opportunity to visit a world-leading research facility, Boehringer Ingelheim, with fellow IMPRS-IS scholars! On Monday, October 14, IMPRS-IS is taking a bus trip to visit to Boehringer Ingelheim's Biberach site, the company's largest research and development center worldwide.
This trip offers a unique opportunity to delve into the world of cutting-edge pharmaceutical data science for health care, learn from industry experts, and explore career pathways in one of the world's leading pharmaceutical companies.
Transportation will be provided from both Tübingen and Stuttgart. Lunch, snacks, and a box dinner is also included.
Why Visit Boehringer Ingelheim?
Learn about their Mission to Improve the Health of Humans and Animals Biberach is the heart of Boehringer Ingelheim's R&D operations. Spanning 415,000 square meters and employing over 7,500 people, this site is a powerhouse of innovation. All research and development stages for chemical active ingredients and biopharmaceuticals are conducted here. Doctoral researchers will gain insights into how Data Science is used across different business units to make an impact and create solutions that help millions of people worldwide live longer, healthier lives.
Learn from others about Transitioning from Academia to Industry For many doctoral researchers, understanding how to transition from academic research to a career in the industry is crucial. This visit will provide valuable perspectives on how scientists at Boehringer Ingelheim have made this transition successfully. You'll learn about the skills and experiences that are highly valued in the pharmaceutical industry and how you can leverage your academic background to pursue a fulfilling career.
Explore Boehringer Ingelheim's Impact Boehringer Ingelheim is dedicated to improving human and animal health through innovative medicines and technologies. Their key areas of interest include respiratory diseases, metabolism, immunology, oncology, and diseases of the central nervous system. The company also develops various software and apps aimed at enhancing health outcomes.
What to Expect
Participants will also get a personalized visit of one of the companies following data science sub-groups. Registrants will be asked to rank their preferences about which sub-group they would most like to visit. Please review the list below before registering.
1. Data & Digital Sciences in Drug Discovery Sciences (DDS2) The DDS2 team drives the digital transformation of Drug Discovery Sciences by developing cutting edge data science and machine learning applications for early drug development. We bring together data experts, data scientists and machine learning researchers to support the development of new pharmacological compounds. This includes, among others, computer vision to characterize complex rodent behavior in general pharmacology studies and the analysis of high-content images to identify secondary pharmacology effects.
2. Global Computational Biology and Digital Sciences (gCBDS) gCBDS is an international team and acts as a global function at Boehringer Ingelheim. The interdisciplinary teams from computational sciences (computational biology, bioinformatics, machine learning genetics, and genomics) develop and apply in silico methods and platforms for drug & target discovery.
3. Medicinal Chemistry / Computational Chemistry - Data Science Team The Computational Chemistry Data Science team uses data science and other computational methods to support the chemists at Boehringer Ingelheim in designing molecules with great properties. The aim is to speed up drug discovery and to make a difference for patients around the world. The team has access to a wealth of chemistry-centric data that was collected over decades of drug discovery research that they analyze with a range of different data-centric methods. In close collaboration with software engineers and other colleagues from Boehringer Ingelheim’s IT department, they integrate the models and calculation engines into easy-to-use tools and work closely with the users to support them in their daily work.
4. IT Enterprise Data & Platforms / Central Data Science Team (CDS) CDS is a diverse team building end-to-end AI solutions from proof of concept to the final product. These solutions are used in all company areas at Boehringer Ingelheim such as R&D, manufacturing, sales, logistics, and HR. In addition, CDS also carries out educational programs on AI and related topics, through courses and workshops. The team has a wide range of difference capabilities and roles. The Data Scientists in CDS are responsible for the conceptualization and implementation of AI projects, while the Machine Learning Engineer owns the infrastructure and Machine Learning lifecycle management. Finally, the Data Value and Ideation Managers or the team take care of the Project management and workshop hosting.
5. Human Pharma Biopharmaceuticals / Engineering & Technology - Data Science Team The Data Science team within HP BioP Engineering & Technology provides data science as service to this organizational unit within Boehringer Ingelheim. The team of Machine Learning Engineers and Data Scientists support the troubleshooting & decision-making using data driven methods. As part of their job, they develop intelligent warning, advisor & control systems and applications (e.g., predictive and preventive maintenance, anomaly detection, etc.) for the colleagues in HP BioP.
About Boehringer Ingelheim Boehringer Ingelheim operates in three main business areas: human pharmaceuticals, animal health, and biopharmaceuticals. With 145 affiliated companies and around 50,000 employees globally, the company has a significant presence on every continent. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies. The Biberach site is one of Europe's largest production facilities for biopharmaceutical active ingredients based on cell cultures, making it a critical hub for the company's global operations.
Note* By registering, you express your interest to participate. In the event interest exceeds attendance capacity, registrations will undergo a review process considering multiple aspects such as motivation, interest, and fit. Individuals who register before July 19 will receive preferential treatment.
We look forward to embarking on this inspiring journey with you and exploring the exciting world of pharmaceutical research and development at Boehringer Ingelheim.
With questions, please reach out (imprs@is.mpg.de).
Registration for this visit has been closed.
Registration Closed
More information